Evidence map›Paper›PMID 36909169›Full record

ArticleFrontiers in pharmacology2023

Functional selectivity of EM-2 analogs at the mu-opioid receptor.

Justyna Piekielna-Ciesielska, Davide Malfacini, Francine Medjiofack Djeujo, Chantal Marconato, Karol Wtorek, Girolamo Calo', Anna Janecka

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Pathology of pain and its implications for therapeutic interventions.Signal transduction and targeted therapy · 2024
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Justyna Piekielna-CiesielskaDepartment of Biomolecular Chemistry, Medical University of Lodz, Lodz, Poland.
Davide MalfaciniDepartment of Pharmaceutical and Pharmacological Sciences, Section of Pharmacology, University of Padova, Padova, Italy.
Francine Medjiofack DjeujoDepartment of Pharmaceutical and Pharmacological Sciences, Section of Pharmacology, University of Padova, Padova, Italy.
Chantal MarconatoDepartment of Pharmaceutical and Pharmacological Sciences, Section of Pharmacology, University of Padova, Padova, Italy.
Karol WtorekDepartment of Biomolecular Chemistry, Medical University of Lodz, Lodz, Poland.
Girolamo Calo'Department of Pharmaceutical and Pharmacological Sciences, Section of Pharmacology, University of Padova, Padova, Italy.
Anna JaneckaDepartment of Biomolecular Chemistry, Medical University of Lodz, Lodz, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mu opioid receptor agonists are the most efficacious pain controlling agents but their use is accompanied by severe side effects. More recent developments indicate that some ligands can differentially activate receptor downstream pathways, possibly allowing for dissociation of analgesia mediated through the G protein from the opioid-related side effects mediated by β-arrestin pathway. In an effort to identify such biased ligands, here we present a series of thirteen endomorphin-2 (EM-2) analogs with modifications in positions 1, 2, and/or 3. All obtained analogs behaved as mu receptor selective agonists in calcium mobilization assay carried out on cells expressing opioid receptors and chimeric G proteins. A Bioluminescence Resonance Energy Transfer (BRET) approach was employed to determine the ability of analogs to promote the interaction of the mu opioid receptor with G protein or β-arrestin 2. Nearly half of the developed analogs showed strong bias towards G protein, in addition four compounds were nearly inactive towards β-arrestin 2 recruitment while blocking the propensity of EM-2 to evoke mu-β-arrestin 2 interaction. The data presented here contribute to our understanding of EM-2 interaction with the mu opioid receptor and of the transductional propagation of the signal. In addition, the generation of potent and selective mu receptor agonists strongly biased towards G protein provides the scientific community with novel tools to investigate the

Indexed as

bias factorBRET assaycalcium mobilization assayendomorphin-2 analogsG proteinopioid receptorsβ-arrestin 2

Identifiers

PMID36909169
PMCPMC9998502

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.